MedTrace Logo

Mycophenolate Mofetil in Myasthenia Gravis

NCT00285350 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-03-25

No results posted yet for this study

Summary

This is a prospective, multi-center, double-blind, placebo-controlled trial to determine the efficacy and safety of mycophenolate mofetil (MM) in combination with prednisone as the initial form of immunosuppression in patients with acquired myasthenia gravis (MG).

Conditions

Interventions

DRUG

mycophenolate mofetil

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • FDA Office of Orphan Products Development

    lead FED

Principal Investigators

  • Donald B Sanders, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2007-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285350 on ClinicalTrials.gov